InterK Peptide Therapeutics

Executive Summary

InterK Peptide Therapeutics is an Australian preclinical biotechnology company specializing in the design and synthesis of non-naturally occurring peptides to modulate immune responses. Founded in 2020 and headquartered in Sydney, the company targets multiple therapeutic areas including autoimmune disorders, cancer immunotherapy, antiviral vaccine adjuvants, and UV-induced skin damage repair. Its peptide engineering platform aims to create novel immunomodulatory therapeutics with enhanced stability and specificity, addressing key limitations of conventional peptide drugs. As a private preclinical entity, InterK has not disclosed funding rounds or valuation, and it operates with a small team of 10-50 employees. The company's broad pipeline across immunology, oncology, infectious diseases, and dermatology underscores its ambition but also reflects the early-stage nature of its programs. Key challenges include advancing candidates through preclinical validation, securing financing for IND-enabling studies, and de-risking platform technology in a competitive peptide therapeutics landscape. Success hinges on demonstrating in vivo proof-of-concept in autoimmune or oncology models and attracting partnership or Series A funding to transition into clinical development.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical proof-of-concept data in autoimmune model60% success
• Q4 2026Completion of Series A financing round50% success
• Q1 2027Announcement of strategic licensing or collaboration deal for antiviral adjuvant platform40% success